Jensen MC - Search Results

1

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ. Jensen MC, et al. Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56. doi: 10.1016/j.bbmt.2010.03.014. Epub 2010 Mar 19. Biol Blood Marrow Transplant. 2010. PMID: 20304086 Free PMC article. Clinical Trial.

2

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.

Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. Jensen M, et al. Biol Blood Marrow Transplant. 1998;4(2):75-83. doi: 10.1053/bbmt.1998.v4.pm9763110. Biol Blood Marrow Transplant. 1998. PMID: 9763110 Free article.

3

Human T lymphocyte genetic modification with naked DNA.

Jensen MC, Clarke P, Tan G, Wright C, Chung-Chang W, Clark TN, Zhang F, Slovak ML, Wu AM, Forman SJ, Raubitschek A. Jensen MC, et al. Mol Ther. 2000 Jan;1(1):49-55. doi: 10.1006/mthe.1999.0012. Mol Ther. 2000. PMID: 10933911 Free article.

4

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.

Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, Wright C, Popplewell L, Raubitschek A, Forman SJ, Jensen MC. Cooper LJ, et al. Among authors: jensen mc. Blood. 2003 Feb 15;101(4):1637-44. doi: 10.1182/blood-2002-07-1989. Epub 2002 Oct 10. Blood. 2003. PMID: 12393484 Free article.

5

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.

Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A. Jensen MC, et al. Cytotherapy. 2003;5(2):131-8. doi: 10.1080/14653240310001028. Cytotherapy. 2003. PMID: 12745575

6

Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.

Wang J, Press OW, Lindgren CG, Greenberg P, Riddell S, Qian X, Laugen C, Raubitschek A, Forman SJ, Jensen MC. Wang J, et al. Among authors: jensen mc. Mol Ther. 2004 Apr;9(4):577-86. doi: 10.1016/j.ymthe.2003.12.011. Mol Ther. 2004. PMID: 15093188 Free article.

7

Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.

Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, Forman SJ, Jensen MC. Cooper LJ, et al. Among authors: jensen mc. Blood Cells Mol Dis. 2004 Jul-Aug;33(1):83-9. doi: 10.1016/j.bcmd.2004.03.003. Blood Cells Mol Dis. 2004. PMID: 15223016 Review.

8

Enhanced transgene expression in quiescent and activated human CD8+ T cells.

Cooper LJ, Topp MS, Pinzon C, Plavec I, Jensen MC, Riddell SR, Greenberg PD. Cooper LJ, et al. Among authors: jensen mc. Hum Gene Ther. 2004 Jul;15(7):648-58. doi: 10.1089/1043034041361217. Hum Gene Ther. 2004. PMID: 15242525

9

Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC. Cooper LJ, et al. Among authors: jensen mc. Blood. 2005 Feb 15;105(4):1622-31. doi: 10.1182/blood-2004-03-1208. Epub 2004 Oct 26. Blood. 2005. PMID: 15507526 Free article.

10

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Kahlon KS, et al. Among authors: jensen mc. Cancer Res. 2004 Dec 15;64(24):9160-6. doi: 10.1158/0008-5472.CAN-04-0454. Cancer Res. 2004. PMID: 15604287

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

173 results

Search Page

Filters